- Home
- DXR vs SERA Comparison
DXR vs SERA Comparison
Compare DXR & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | SERA |
|---|---|---|
| Founded | 1970 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Precision Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 77.2M |
| IPO Year | 1995 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DXR | SERA |
|---|---|---|
| Price | $11.30 | $2.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 12.7K | ★ 22.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.66 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | $77,000.00 |
| Revenue This Year | $44,935.22 | $25.84 |
| Revenue Next Year | N/A | $715.79 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.10 | $1.37 |
| 52 Week High | $14.76 | $4.34 |
Technical Indicators
Market Signals| Indicator | DXR | SERA |
|---|---|---|
| Relative Strength Index (RSI) | 36.19 | 22.47 |
| Support Level | $10.00 | $1.37 |
| Resistance Level | $11.32 | $2.00 |
| Average True Range (ATR) | 0.37 | 0.20 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 14.71 | 4.61 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About SERA Sera Prognostics Inc.
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.